Cargando…

Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas

PURPOSE: In patients with indolent B‐cell non‐Hodgkin's lymphoma (B‐NHL), one course of low‐dose radiotherapy (LD‐RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD‐RT when repeated remains to be determinate. This study aims to assess the efficacy of repeate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleh, Khalil, Michot, Jean‐Marie, Schernberg, Antoine, Lazarovici, Julien, Chahine, Claude, Danu, Alina, Khalife‐Saleh, Nadine, Rossignol, Julien, Ghez, David, Martin, Valentine, Mazeron, Renaud, Fermé, Christophe, Boros, Angela, Ribrag, Vincent, Girinsky, Theodore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286454/ https://www.ncbi.nlm.nih.gov/pubmed/32249547 http://dx.doi.org/10.1002/cam4.2796

Ejemplares similares

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma
por: Quivoron, Cyril, et al.
Publicado: (2022)

When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes
por: Willekens, Christophe, et al.
Publicado: (2023)

Updates in the Treatment of Peripheral T-Cell Lymphomas
por: Saleh, Khalil, et al.
Publicado: (2021)

Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study
por: Andreozzi, Fabio, et al.
Publicado: (2023)

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
por: Imber, Brandon S., et al.
Publicado: (2021)

Reduced frequency of cytotoxic CD56(dim) CD16(+) NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma
por: Pánisová, Elena, et al.
Publicado: (2021)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma
por: Hoppe, Bradford S., et al.
Publicado: (2020)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Role of imaging to choose treatment: Wednesday 5 October 2005, 08:30–10:00
por: Fermé, Christophe, et al.
Publicado: (2005)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Hodgkins disease
por: Ferme, C, et al.
Publicado: (2001)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 gy) and intraoperative radiation therapy (15 gy) in patients with primarily resectable pancreatic cancer - NEOPANC
por: Roeder, Falk, et al.
Publicado: (2012)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma
por: Hidman, Josefin, et al.
Publicado: (2023)

Draft Genome Sequences of Dysgonomonas sp. Strains GY75 and GY617, Isolated from the Hindgut of Reticulitermes flavipes
por: Bridges, Charles M., et al.
Publicado: (2021)

New developments in the management of head and neck cancer – impact of pembrolizumab
por: Saleh, Khalil, et al.
Publicado: (2018)

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity
por: Murthy, Vedang, et al.
Publicado: (2017)

Kidney Cell DNA Damage Caused By Combined Exposure To Volatile Anaesthetics and 1 Gy Or 2 Gy Radiotherapy Dose in Vivo
por: Benković, Vesna, et al.
Publicado: (2022)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction((α/β=3Gy)) at 2 cm(3) of vagina
por: Aguilera, María del Valle, et al.
Publicado: (2018)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity
por: Jolnerovski, Maria, et al.
Publicado: (2017)

A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer
por: Lee, Sea-Won, et al.
Publicado: (2016)

Comparison of 5 × 5 Gy and 10 × 3 Gy for metastatic spinal cord compression using data from three prospective trials
por: Rades, Dirk, et al.
Publicado: (2021)

The Gypsy Database (GyDB) of mobile genetic elements
por: Lloréns, C., et al.
Publicado: (2008)

Circumpolar ocean stability on Mars 3 Gy ago
por: Schmidt, Frédéric, et al.
Publicado: (2022)

The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
por: M’kacher, Radhia, et al.
Publicado: (2018)

Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II)
por: Widder, J, et al.
Publicado: (2005)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_37ps3tdtdpfj001oapf1eia1e1